These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
469 related articles for article (PubMed ID: 15339678)
1. Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA leukemia groups. Amadori S; Suciu S; Willemze R; Mandelli F; Selleslag D; Stauder R; Ho A; Denzlinger C; Leone G; Fabris P; Muus P; Vignetti M; Hagemeijer A; Beeldens F; Anak O; De Witte T; ; Haematologica; 2004 Aug; 89(8):950-6. PubMed ID: 15339678 [TBL] [Abstract][Full Text] [Related]
2. Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years. Candoni A; Martinelli G; Toffoletti E; Chiarvesio A; Tiribelli M; Malagola M; Piccaluga PP; Michelutti A; Simeone E; Damiani D; Russo D; Fanin R Leuk Res; 2008 Dec; 32(12):1800-8. PubMed ID: 18621416 [TBL] [Abstract][Full Text] [Related]
3. Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17). Amadori S; Suciu S; Stasi R; Salih HR; Selleslag D; Muus P; De Fabritiis P; Venditti A; Ho AD; Lübbert M; Thomas X; Latagliata R; Halkes CJ; Falzetti F; Magro D; Guimaraes JE; Berneman Z; Specchia G; Karrasch M; Fazi P; Vignetti M; Willemze R; de Witte T; Marie JP J Clin Oncol; 2013 Dec; 31(35):4424-30. PubMed ID: 24127442 [TBL] [Abstract][Full Text] [Related]
4. Gemtuzumab ozogamicin in combination with attenuated doses of standard induction chemotherapy can successfully induce complete remission without increasing toxicity in patients with acute myeloid leukemia aged 55 or older. Eom KS; Kim HJ; Min WS; Lee S; Min CK; Cho BS; Kim SY; Kim YJ; Lee DG; Choi SM; Cho SG; Kim DW; Lee JW; Shin WS; Kim CC Eur J Haematol; 2007 Nov; 79(5):398-404. PubMed ID: 17916082 [TBL] [Abstract][Full Text] [Related]
5. Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013). de Witte T; Suciu S; Meert L; Halkes C; Selleslag D; Bron D; Amadori S; Willemze R; Muus P; Baron F Ann Hematol; 2015 Dec; 94(12):1981-9. PubMed ID: 26410352 [TBL] [Abstract][Full Text] [Related]
6. High response rate for treatment with gemtuzumab ozogamicin and cytarabine in elderly patients with acute myeloid leukemia and favorable and intermediate-I cytogenetic risk. Tavor S; Rahamim E; Sarid N; Rozovski U; Gibstein L; Aviv F; Kirsner I; Naparstek E Clin Lymphoma Myeloma Leuk; 2012 Dec; 12(6):438-43. PubMed ID: 23017331 [TBL] [Abstract][Full Text] [Related]
7. Fractionated doses of gemtuzumab ozogamicin combined with 3 + 7 induction chemotherapy as salvage treatment for young patients with acute myeloid leukemia in first relapse. Malfuson JV; Konopacki J; Thepenier C; Eddou H; Foissaud V; de Revel T Ann Hematol; 2012 Dec; 91(12):1871-7. PubMed ID: 22820971 [TBL] [Abstract][Full Text] [Related]
8. Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia. Chevallier P; Delaunay J; Turlure P; Pigneux A; Hunault M; Garand R; Guillaume T; Avet-Loiseau H; Dmytruk N; Girault S; Milpied N; Ifrah N; Mohty M; Harousseau JL J Clin Oncol; 2008 Nov; 26(32):5192-7. PubMed ID: 18854573 [TBL] [Abstract][Full Text] [Related]
9. Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: results of a prospective, pilot, multi-centre trial and comparison with a historical cohort of patients. Clavio M; Vignolo L; Albarello A; Varaldo R; Pierri I; Catania G; Balocco M; Michelis G; Miglino M; Manna A; Balleari E; Carella AM; Sessarego M; Van Lint MT; Bacigalupo A; Gobbi M Br J Haematol; 2007 Jul; 138(2):186-95. PubMed ID: 17593025 [TBL] [Abstract][Full Text] [Related]
10. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Bross PF; Beitz J; Chen G; Chen XH; Duffy E; Kieffer L; Roy S; Sridhara R; Rahman A; Williams G; Pazdur R Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481 [TBL] [Abstract][Full Text] [Related]
11. Gemtuzumab ozogamicin with cytarabine and mitoxantrone as a third-line treatment in a poor prognosis group of adult acute myeloid leukemia patients: a single-center experience. Specchia G; Pastore D; Carluccio P; Spinosa G; Giannoccaro M; Rizzi R; Mestice A; Liso V Ann Hematol; 2007 Jun; 86(6):425-8. PubMed ID: 17364181 [TBL] [Abstract][Full Text] [Related]
12. Comparative efficacy and safety of gemtuzumab ozogamicin monotherapy and high-dose cytarabine combination therapy in patients with acute myeloid leukemia in first relapse. Leopold LH; Berger MS; Cheng SC; Cortes-Franco JE; Giles FJ; Estey EH Clin Adv Hematol Oncol; 2003 Apr; 1(4):220-5. PubMed ID: 16224410 [TBL] [Abstract][Full Text] [Related]
13. The role of gemtuzumab ozogamicin in acute leukaemia therapy. Tsimberidou AM; Giles FJ; Estey E; O'Brien S; Keating MJ; Kantarjian HM Br J Haematol; 2006 Feb; 132(4):398-409. PubMed ID: 16412015 [TBL] [Abstract][Full Text] [Related]
14. First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients. Piccaluga PP; Martinelli G; Rondoni M; Malagola M; Gaitani S; Visani G; Baccarani M Leuk Res; 2004 Sep; 28(9):987-90. PubMed ID: 15234577 [TBL] [Abstract][Full Text] [Related]
15. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol. Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387 [TBL] [Abstract][Full Text] [Related]
16. Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. Löwenberg B; Beck J; Graux C; van Putten W; Schouten HC; Verdonck LF; Ferrant A; Sonneveld P; Jongen-Lavrencic M; von Lilienfeld-Toal M; Biemond BJ; Vellenga E; Breems D; de Muijnck H; Schaafsma R; Verhoef G; Döhner H; Gratwohl A; Pabst T; Ossenkoppele GJ; Maertens J; ; ; Blood; 2010 Apr; 115(13):2586-91. PubMed ID: 20103782 [TBL] [Abstract][Full Text] [Related]
17. Phase I trial of gemtuzumab ozogamicin in intensive combination chemotherapy for relapsed or refractory adult acute myeloid leukemia (AML): Japan Adult Leukemia Study Group (JALSG)-AML206 study. Usui N; Takeshita A; Nakaseko C; Dobashi N; Fujita H; Kiyoi H; Kobayashi Y; Sakura T; Yahagi Y; Shigeno K; Ohwada C; Miyazaki Y; Ohtake S; Miyawaki S; Naoe T; Ohnishi K; Cancer Sci; 2011 Jul; 102(7):1358-65. PubMed ID: 21585619 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and toxicity of gemtuzumab ozogamicin in patients with acute myeloid leukemia. van der Heiden PL; Jedema I; Willemze R; Barge RM Eur J Haematol; 2006 May; 76(5):409-13. PubMed ID: 16480432 [TBL] [Abstract][Full Text] [Related]
19. A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse. Moore J; Seiter K; Kolitz J; Stock W; Giles F; Kalaycio M; Zenk D; Marcucci G Leuk Res; 2006 Jul; 30(7):777-83. PubMed ID: 16730060 [TBL] [Abstract][Full Text] [Related]